[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Middle East University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":337},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,67,88,108,130,148,170,192,213,234,255,273,295,316],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644789","the-effects-of-10-weeks-pilates-exercise-on-pulmonary-function-and-quality-of-life-in-postmenopausal-women-100644789",false,"NCT07672548","The Effects of 10-weeks Pilates Exercise on Pulmonary Function and Quality of Life in Postmenopausal Women","The Effects of 10-weeks Pilates Exercise on Pulmonary Function and Quality of Life in Postmenopausal Women With Normal Body Mass Idex: A Randomized Controlled Trial.","RCT","Inclusion Criteria:\n\n* Postmenopausal women aged 50-60 years.\n* Women who suffered from breathing problems\n* Women with normal body mass index (BMI) 18 to 25 kg\u002Fm².\n* Women not related to any other studies.\n\nExclusion Criteria:\n\n* Comorbidities such as cardiac or chest diseases (critically ill patients).\n* Receiving hormone replacement therapy.\n* BMI ˃ 25 kg\u002Fm² or ˂ 18 kg\u002Fm²,\n* Age greater than 60 years or less than 50 years,\n* Use of sedatives, tranquilizers, or antidepressant medications,\n* Musculoskeletal disorders.",true,"FEMALE","50 Years","60 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will investigate the effect of 10-weeks Pilates exercise on pulmonary function and quality of life in postmenopausal women with normal Body mass index",[29],"Post Menopausal","RECRUITING","2026-06-26",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":34},"2026-06-01",{"date":38,"type":23},"2026-10-01",{"name":40,"class":41},"Middle East University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100641670","effect-of-antigravity-treadmill-training-on-cardiorespiratory-fitness-and-lower-limb-function-in-incomplete-spinal-cord-injury-100641670","NCT07653529","Effect of Antigravity Treadmill Training on Cardiorespiratory Fitness and Lower Limb Function in Incomplete Spinal Cord Injury","Effect of Antigravity Treadmill Locomotor Training on Cardiorespiratory Fitness and Lower Limb Function in Patients With Incomplete Spinal Cord Injury","Antigravity","Inclusion Criteria:\n\nIncomplete spinal cord injury (ASIA C or D)\n\n* Injury duration more than 3 months\n* Ability to stand with or without assistance\n* Medically stable condition\n\nExclusion Criteria:\n\n* Complete spinal cord injury\n\n  * Severe cardiopulmonary disorders\n  * Severe osteoporosis or fractures\n  * Severe cognitive impairment\n  * Other neurological disorders affecting gait","ALL","40 Years",{"count":54,"type":23},60,[26],"This study aims to investigate the effect of locomotor training using an antigravity treadmill on cardiorespiratory fitness and lower limb function in patients with incomplete spinal cord injury.",[58],"Incomplete Spinal Cord Injury (SCI)","NOT_YET_RECRUITING","2026-06-12",{"date":62,"type":34},"2026-06-17",{"date":60,"type":23},{"date":65,"type":23},"2026-12-15",{"name":40,"class":41},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":51,"minAge":74,"maxAge":20,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100642545","effect-of-high-intensity-focused-electromagnetic-therapy-on-balance-and-quality-of-life-in-patients-with-multiple-sclerosis-100642545","NCT07646912","Effect of High-Intensity Focused Electromagnetic Therapy on Balance and Quality of Life in Patients With Multiple Sclerosis","Effect of High-Intensity Focused Electromagnetic Technology on Balance and Quality of Life in Patients With Multiple Sclerosis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Confirmed clinical diagnosis of Multiple Sclerosis according to the revised McDonald criteria.\n* Expanded Disability Status Scale score range between 3.0 and 5.5.\n* Clinically stable condition with no neurological relapses or corticosteroid therapy within the past 3 months.\n\nExclusion Criteria:\n\n* Presence of pacemakers, internal defibrillators, or metallic implants in the torso\u002Fabdominal region.\n* Severe cognitive impairment interfering with the understanding of instructions or questionnaires.\n* Other concomitant neurological or musculoskeletal orthopedic conditions that independently affect balance or gait.\n* Severe visual deficits or uncorrected vestibular disorders.\n* Pregnancy.","18 Years",{"count":54,"type":23},[26],"Evaluate the effect of High-Intensity Focused Electromagnetic Therapy on dynamic balance, fall risk, core muscle function, and quality of life in patients with multiple sclerosis.",[79],"Multiple Sclerosis","2026-06-09",{"date":82,"type":34},"2026-06-15",{"date":84,"type":23},"2026-06-22",{"date":86,"type":23},"2026-10-14",{"name":40,"class":41},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":74,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100643176","manual-diaphragmatic-release-on-exercise-capacity-and-quality-of-life-in-women-with-fibromyalgia-100643176","NCT07641166","Manual Diaphragmatic Release on Exercise Capacity and Quality of Life in Women With Fibromyalgia","Effect of Manual Diaphragmatic Release on Exercise Capacity and Quality of Life in Women With Fibromyalgia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Confirmed clinical diagnosis of fibromyalgia fulfilling the American College of Rheumatology diagnostic criteria.\n* Sedentary or low physical activity status (not participating in structured exercise programs within the past 3 months).\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities (e.g., major depressive disorder with active suicidal ideation) or cognitive impairments.\n* Presence of comorbid rheumatologic or autoimmune conditions that overlap with muscle\u002Fjoint symptoms (e.g., severe rheumatoid arthritis, systemic lupus erythematosus).\n* Primary chronic respiratory\u002Fchest diseases (e.g., severe COPD or active asthma).\n* Cardiovascular disorders or uncontrolled hypertension.\n* Pregnancy.","55 Years",{"count":54,"type":23},[26],"Evaluate the effect of manual diaphragmatic release on exercise capacity, inspiratory muscles strength, symptoms severity, and health-related quality of life in women diagnosed with fibromyalgia.",[100],"Fibromyalgia","2026-06-08",{"date":103,"type":34},"2026-06-11",{"date":62,"type":23},{"date":106,"type":23},"2026-11-08",{"name":40,"class":41},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100643742","effect-of-tecar-therapy-on-pain-balance-and-quality-of-life-in-elderly-men-with-knee-osteoarthritis-100643742","NCT07633795","Effect of TECAR Therapy on Pain, Balance, and Quality of Life in Elderly Men With Knee Osteoarthritis","Effect of TECAR Therapy on Pain, Balance, and Quality of Life in Elderly Men With Knee Osteoarthritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical and radiographic diagnosis of mild and moderate bilateral or unilateral knee osteoarthritis meeting the American College of Rheumatology (ACR) criteria.\n* Presence of chronic knee pain lasting for more than 6 months.\n* Ability to ambulate independently with or without an assistive device.\n\nExclusion Criteria:\n\n* Severe knee osteoarthritis (grade IV) requiring imminent surgical joint replacement.\n* History of previous knee arthroplasty, internal fixation, or significant trauma to the affected lower extremity.\n* Presence of pacemakers, metallic implants in the knee region, or severe. - peripheral vascular disease (absolute contraindications for TECAR therapy).\n* Intra-articular injections (corticosteroids, platelet-rich plasma, or hyaluronic acid) into the knee within the past 3 months.\n* Cognitive impairment or systemic inflammatory conditions (e.g., rheumatoid arthritis).","MALE","65 Years","75 Years",{"count":119,"type":23},80,[26],"Evaluate the effect of TECAR therapy combined with traditional physiotherapy on pain, balance, and quality of life in elderly men with knee osteoarthritis .",[123],"Knee Osteoarthritis","2026-06-02",{"date":101,"type":34},{"date":82,"type":23},{"date":128,"type":23},"2026-10-18",{"name":40,"class":41},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":51,"minAge":74,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100642970","high-intensity-focused-electromagnetic-therapy-on-patients-with-patellofemoral-pain-syndrome-100642970","NCT07633782","High-Intensity Focused Electromagnetic Therapy on Patients With Patellofemoral Pain Syndrome","Effect of High-Intensity Focused Electromagnetic Therapy on Pain and Quality of Life in Patients With Patellofemoral Pain Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical diagnosis of patellofemoral pain syndrome (anterior or peripatellar knee pain aggravated by at least two activities such as stair climbing, prolonged sitting, squatting, or running).\n* Symptoms persisting for at least 3 months.\n\nExclusion Criteria:\n\n* History of previous knee surgery or trauma (e.g., ligamentous laxity, meniscal tear, or patellar fracture).\n* Concomitant knee pathology (e.g., tibiofemoral osteoarthritis, patellar tendinopathy, or plica syndrome).\n* Presence of metallic implants, pacemakers, or electrical medical devices in the body .\n* Recent corticosteroid or hyaluronic acid injection into the affected knee within the last 3 months.\n* Pregnancy.","45 Years",{"count":54,"type":23},[26],"Evaluate the effect of High-Intensity Focused Electromagnetic Therapy on pain, quadriceps strength, and quality of life in patients with patellofemoral pain syndrome",[142],"Patellofemoral Pain Syndrome",{"date":101,"type":34},{"date":60,"type":23},{"date":146,"type":23},"2026-10-08",{"name":40,"class":41},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":51,"minAge":74,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":24,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":42},"100631190","enhancing-pain-management-among-patients-diagnosed-with-stage-iii-and-stage-iv-of-breast-cancer-the-power-of-immersive-and-non-immersive-virtual-reality-driven-interactive-guided-imagery-100631190","NCT07497451","Enhancing Pain Management Among Patients Diagnosed With Stage III and Stage IV of Breast Cancer: The Power of Immersive and Non-Immersive Virtual Reality-Driven Interactive Guided Imagery","Enhancing Pain Management Among Patients Diagnosed With Stage III and Stage IV of Breast Cancer: The Power of Non-Immersive Virtual Reality-Driven Interactive Guided Imagery: A Randomized Controlled Trial (RCT)","Inclusion Criteria\n\n* Patients diagnosed with advanced stage of breast cancer; based on pathological analysis (this Data from electronic medical record system).\n* Undergoing treatment in the selected Hospital\n* Age group \\>18 years of age (Adult)\n* Hospitalized patient at the selected study setting\n* Available at the time of data collection; the minimum expected admission time should be no less than 5 days, as the intervention is planned to last for 5 days.\n* Able to sign the consent form.\n* Willing to comply with study procedures and instructions.\n* has cancer pain. Exclusion Criteria\n* Individuals who are experiencing difficulties in their ability to hear or have a complete loss of hearing.\n* Individuals who suffer from extreme visual impairment or complete loss of vision.\n* Not willing to participate in the study.\n* Patient with Glasgow coma scale \\\u003C 15\n* Individuals who experience persistent and uncontrollable feelings of nausea, vomiting, or dizziness, individuals with a background of motion sickness (Rational for exclusion: According to previous studies, the utilization of VR intervention may have adverse effects, including Dizziness, nausea, vomiting, and motion sickness (Simón-Vicente et al., 2022).As a result, in order to prevent the exacerbation of these symptoms among patients, they will not be included in the VR intervention)\n* Individuals with a history of seizures or epilepsy (Rational for exclusion: Individuals diagnosed with epilepsy have frequently been excluded from the participation in virtual reality (VR) research due to the concern that engaging with VR technology could potentially induce seizures in those who have photosensitive epilepsy (Gray et al., 2023)\n* A patient who has an injury at their eyes, face, or neck that hinders their ability to comfortably utilize virtual reality (VR) hardware or software or poses a safety risk when using the hardware (such as having open sores, wounds, or a skin rash on their face).",{"count":156,"type":23},90,[26],"Cancer-related pain is one of the most common and distressing symptoms experienced by patients with advanced cancer, particularly among women diagnosed with advanced breast cancer. Pain associated with cancer may arise from tumor progression, metastasis, or cancer treatments, and it often has a substantial negative impact on patients' physical functioning, emotional well-being, and overall quality of life. Although pharmacological pain management strategies remain the primary approach for managing cancer-related pain, many patients continue to report inadequate pain relief or experience undesirable side effects from medications. For this reason, healthcare providers and researchers are increasingly exploring complementary and non-pharmacological interventions that can be used alongside standard pain management strategies.\n\nCurrent clinical practice for cancer pain management commonly follows the analgesic ladder recommended by the World Health Organization, which involves a stepwise approach using non-opioid analgesics, weak opioids, and strong opioids depending on the severity of the patient's pain. While this approach has significantly improved pain control in many patients, it does not completely eliminate pain in all cases, and additional supportive interventions are often required. In recent years, digital health technologies such as virtual reality (VR) have emerged as promising tools that may support pain management through distraction, relaxation, and cognitive engagement.\n\nVirtual reality is an interactive computer-generated environment that can simulate real or imaginary settings and allow users to experience immersive or semi-immersive sensory stimulation. VR-based interventions have gained increasing attention in healthcare due to their potential to reduce pain perception by diverting attention away from painful stimuli and promoting psychological relaxation. In particular, VR-assisted guided imagery interventions have been proposed as a therapeutic approach that combines visual and auditory stimuli with relaxation techniques to enhance patients' cognitive engagement and emotional comfort.\n\nVR technology can be delivered through different levels of immersion. Immersive VR typically uses a head-mounted display to create a fully interactive three-dimensional environment that surrounds the user and blocks out external stimuli, providing a highly engaging experience. In contrast, non-immersive VR systems present virtual environments through computer screens or similar devices, allowing users to remain aware of their physical surroundings while interacting with digital content. Although both approaches may contribute to pain reduction through distraction and relaxation mechanisms, limited evidence exists regarding the comparative effectiveness of immersive versus non-immersive VR interventions in the management of cancer-related pain.\n\nTherefore, the purpose of this study is to evaluate the effectiveness of immersive and non-immersive virtual reality-assisted guided imagery interventions in reducing cancer-related pain among patients with advanced breast cancer in Jordan. The study aims to determine whether these interventions can provide additional benefits when used alongside standard cancer pain management practices.\n\nThis study will employ a quantitative quasi-experimental pre-post design with three study groups: an immersive virtual reality intervention group, a non-immersive virtual reality-assisted guided imagery group, and a control group receiving standard cancer pain management care. Participants in both intervention groups will engage in a 45-minute virtual reality session consisting of guided imagery experiences designed to promote relaxation and distraction from pain. The immersive VR group will use head-mounted display technology to experience a fully immersive 360-degree virtual environment, while the non-immersive VR group will view similar virtual content using a computer-based display system with audio support.\n\nPain intensity will be measured using the Arabic version of the Numerical Pain Rating Scale (NPRS) before the intervention and immediately after the intervention. In addition, symptoms associated with simulator sickness, such as nausea, dizziness, and visual discomfort, will be assessed using the Simulator Sickness Questionnaire (SSQ) to evaluate the safety and tolerability of the VR interventions.\n\nThe study will be conducted among adult patients diagnosed with advanced breast cancer who are receiving care at a cancer pain management clinic in a large public hospital in Jordan. Eligible participants will be adults aged 18 years or older who are experiencing cancer-related pain and are able to participate in the intervention sessions. A total of 90 participants will be recruited and allocated equally across the three study groups.\n\nThe findings of this study are expected to contribute to the growing body of evidence regarding the role of virtual reality technologies in suppo",[160,161],"Cancer Pain","Virtual Reality Immersion","2026-03-24",{"date":164,"type":34},"2026-03-27",{"date":166,"type":23},"2026-03-20",{"date":168,"type":23},"2026-07-20",{"name":40,"class":41},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":18,"minAge":177,"maxAge":137,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":42},"100628787","resistance-training-on-depression-and-quality-of-life-in-type-1-diabetic-women-100628787","NCT07466186","Resistance Training on Depression and Quality of Life in Type 1 Diabetic Women","Effect of Resistance Training on Depression and Quality of Life in Type 1 Diabetic Women","Inclusion Criteria:\n\n1. Diagnosis of type 1 diabetes for more than 5 years\n2. Unchanged insulin doses for no less than three months\n3. Good glycemic control, defined as glycated hemoglobin levels below 7%\n4. Minimal to moderate depressive symptoms\n5. Sleep quality impairment\n\nExclusion Criteria:\n\nPresence of other types of diabetes, unstable cardiopulmonary conditions, recent neurological or musculoskeletal problems affecting exercise, pregnancy, postmenopausal status, and the use of sedatives or antidepressants.","20 Years",{"count":179,"type":23},78,[26],"Find out the effects of resistance training on depression, sleep quality, and quality of life in women with type 1 diabetes mellitus",[183],"Type 1 Diabetes Mellitus","2026-03-08",{"date":186,"type":34},"2026-03-12",{"date":188,"type":23},"2026-03-18",{"date":190,"type":23},"2026-07-28",{"name":40,"class":41},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":115,"minAge":199,"maxAge":19,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100617870","tecar-therapy-on-pain-and-quality-of-life-in-men-with-chronic-prostatitischronic-pelvic-pain-syndrome-100617870","NCT07324239","TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome","Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Presence of chronic prostatitis\u002Fchronic pelvic pain symptoms for more than 6 months.\n* Ages will be ranged from 30 to 50 years old.\n\nExclusion Criteria:\n\n1. Urinary and seminal infections.\n2. Recent parenteral steroid administration.\n3. Prior prostate or pelvic surgery.\n4. Lower urinary tract disorders such as bladder stones.\n5. Implanted electronic devices as pacemakers.\n6. Sensory loss over the perineum.","30 Years",{"count":54,"type":23},[26],"Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis\u002Fchronic pelvic pain syndrome.",[204],"Prostatitis","2025-12-23",{"date":207,"type":34},"2026-01-07",{"date":209,"type":23},"2026-01-02",{"date":211,"type":23},"2026-04-07",{"name":40,"class":41},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":51,"minAge":199,"maxAge":20,"enrollmentInfo":220,"targetDuration":4,"studyType":24,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100614361","high-intensity-focused-electromagnetic-therapy-on-pain-and-quality-of-life-in-patients-with-lumbar-disc-prolapse-100614361","NCT07278596","High Intensity Focused Electromagnetic Therapy on Pain and Quality of Life in Patients With Lumbar Disc Prolapse","Effect of High Intensity Focused Electromagnetic Therapy on Pain and Quality of Life in Patients With Lumbar Disc Prolapse: a Randomized Controlled Trial","Inclusion Criteria:\n\n* A confirmed diagnosis of lumbar disc prolapse by clinical and radiological evaluation.\n* Ages between 30 and 60 years.\n* A history of low back pain for at least three months.\n* A body mass index less than 30 kg\u002Fm².\n\nExclusion Criteria:\n\n* History of spinal surgery or recent traumatic spinal injury.\n* Severe spinal canal stenosis or progressive neurological deficits.\n* Known malignancy, infection, or inflammatory arthritis affecting the spine.\n* Presence of implanted metal devices or pacemakers contraindicating electromagnetic therapy.\n* Pregnancy or suspected pregnancy.\n* Cognitive or psychological disorders that impair communication or ability to follow instructions",{"count":54,"type":23},[26],"Determine whether high intensity focused electromagnetic therapy has a significant effect on pain and quality of life in patients with lumbar disc prolapse.",[224,225],"Back Pain Lower Back","Magnetic Therapy","2025-12-01",{"date":228,"type":34},"2025-12-12",{"date":230,"type":23},"2025-12-07",{"date":232,"type":23},"2026-04-01",{"name":40,"class":41},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":51,"minAge":74,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":4},"100581347","neurorealign-therapy-for-cognitive-rehabilitation-in-patients-with-stroke-100581347","NCT06849128","NeuroReAlign Therapy for Cognitive Rehabilitation in Patients with Stroke","Effects of NeuroReAlign Therapy on Cognition in Patients with Stroke: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with ischemic or hemorrhagic stroke\n* Have a stroke more than 6 months\n* Age between 18 and 70\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairments\n* Patients cannot walk independently","70 Years",{"count":22,"type":23},[26],"The goal of this randomized controlled trial is to investigate the effects of NeuroReAlign Therapy on cognition in stroke survivors in the chronic stage (\\>6 months). The study will include male and female participants aged 18-70 years.\n\nThe main questions it aims to answer are:\n\nDoes NeuroReAlign Therapy improve cognition in stroke survivors compared to conventional physiotherapy? Researchers will compare NeuroReAlign Therapy to conventional cognitive therapy to determine its effects on cognition.\n\nParticipants will:\n\nUndergo NeuroReAlign Therapy or conventional cognitive therapy for 4 weeks. Have their cognition evaluated using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Trail Making Test (TMT), Stroop Test, Digit Span Test, and Verbal Fluency Test (VFT).\n\nComplete outcome assessments at baseline and after the intervention (week 4).",[246],"Stroke","2025-03-13",{"date":249,"type":34},"2025-03-18",{"date":251,"type":23},"2025-03-15",{"date":253,"type":23},"2025-04-30",{"name":40,"class":41},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":51,"minAge":74,"maxAge":241,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100581345","neurorealign-therapy-for-balance-and-gait-rehabilitation-in-stroke-survivors-100581345","NCT06849102","NeuroReAlign Therapy for Balance and Gait Rehabilitation in Stroke Survivors","Effects of NeuroReAlign Therapy on Balance and Gait in Stroke Survivors: a Randomized Controlled Trial",{"count":22,"type":23},[26],"The goal of this randomized controlled trial is to investigate the effects of NeuroReAlign Therapy on balance and gait in stroke survivors in the chronic stage (\\>6 months). The study will include male and female participants aged 18-70 years.\n\nThe main questions it aims to answer are:\n\nDoes NeuroReAlign Therapy improve balance in stroke survivors compared to conventional physiotherapy? Does NeuroReAlign Therapy enhance gait performance more effectively than conventional physiotherapy? Researchers will compare NeuroReAlign Therapy to conventional physiotherapy to determine its effects on balance and gait.\n\nParticipants will:\n\nUndergo NeuroReAlign Therapy or conventional physiotherapy for 4 weeks. Have their balance assessed using the Berg Balance Scale (BBS), Activities-Specific Balance Confidence Scale (ABC Scale), and Fear of Falling Questionnaire (FoFQ).\n\nHave their gait evaluated using the Dynamic Gait Index (DGI), Rivermead Mobility Index (RMI), Timed Up and Go (TUG), 6-Minute Walk Test (6MWT), and 10-Meter Walk Test (10MWT).\n\nComplete outcome assessments at baseline and after the intervention (week 4).",[246],"2025-02-24",{"date":267,"type":34},"2025-02-27",{"date":269,"type":23},"2025-03-01",{"date":271,"type":23},"2025-04-20",{"name":40,"class":41},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":18,"minAge":137,"maxAge":20,"enrollmentInfo":280,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100573062","breathing-exercises-on-depression-in-postmenopausal-women-100573062","NCT06741384","Breathing Exercises on Depression in Postmenopausal Women","Effect of Breathing Exercises on Depression and Sexual Function in Postmenopausal Women","Inclusion Criteria:\n\n* Minimum of 3 years after menopause.\n* Mild to moderate depression.\n* Mild to moderate sexual dysfunction.\n* Their ages will be ranged from 45 to 60 years old.\n* Their BMI will be less than 30 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Prolapse of the pelvic organs.\n* Pelvic tumors.\n* Vaginal infections.\n* Musculoskeletal\u002F neurological limitations to exercise.\n* Psychiatric disorders.\n* Unstable cardiovascular conditions.\n* Diabetes.",{"count":54,"type":23},[26],"Evaluate the effect of breathing exercises on depression and sexual function in postmenopausal women",[284,285,286],"Postmenopausal","Depressive Symptom","Breathing Exercises","2024-12-18",{"date":289,"type":34},"2024-12-20",{"date":291,"type":23},"2024-12-26",{"date":293,"type":23},"2025-03-25",{"name":40,"class":41},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":20,"enrollmentInfo":302,"targetDuration":4,"studyType":24,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100571112","manual-diaphragmatic-release-on-ventilatory-functions-in-women-with-rheumatoid-arthritis-100571112","NCT06716008","Manual Diaphragmatic Release on Ventilatory Functions in Women With Rheumatoid Arthritis","Effect of Manual Diaphragmatic Release on Ventilatory Functions in Women With Rheumatoid Arthritis","Inclusion Criteria:\n\n* All women will have rheumatoid arthritis for more than 2 years with low-to-moderate disease activity.\n* Normal to mildly restrictive lung pattern.\n* Their ages will be ranged from 40 to 60 years old.\n* Their body mass index will be less than 30 Kg\u002Fm2.\n\nExclusion Criteria:\n\n* Chronic chest diseases.\n* Recent parenteral steroid administration.\n* Cardiovascular disorders (coronary heart disease, heart failure, cardiac arrhythmia, peripheral arterial disease, uncontrolled hypertension).\n* Smokers.\n* Joint surgery (in the preceding 6 months).\n* Musculoskeletal\u002F neurological limitations to exercise.\n* Pregnancy.",{"count":54,"type":23},[26],"Evaluate the effect of manual diaphragmatic release on ventilatory functions in women with rheumatoid arthritis",[306,307],"Rheumatic Arthritis","Lung Function","2024-12-04",{"date":310,"type":34},"2024-12-09",{"date":312,"type":23},"2024-12-03",{"date":314,"type":23},"2025-04-01",{"name":40,"class":41},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":18,"minAge":199,"maxAge":52,"enrollmentInfo":323,"targetDuration":4,"studyType":24,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":4},"100565820","aerobic-training-on-lung-function-in-fibromyalgia-100565820","NCT06647147","Aerobic Training on Lung Function in Fibromyalgia","Impact of Aerobic Training on Lung Function in Women With Fibromyalgia","Inclusion Criteria:\n\n* Well controlled fibromyalgia.\n* Mild restrictive lung affection.\n* Body mass index less than 30kg\u002Fm2.\n* Moderate level of physical activity.\n\nExclusion Criteria:\n\n* Any chest diseases.\n* Musculoskeletal\u002F neurological limitations to exercise.\n* Smokers.\n* Pregnant.",{"count":119,"type":23},[26],"Exploring the effect of aerobic exercises on lung function, chest movement, and exercise capacity in women suffering from fibromyalgia.",[327,328],"Fibromyalgia (FM)","Respiration Disorders","2024-10-16",{"date":331,"type":34},"2024-10-17",{"date":333,"type":23},"2024-11-25",{"date":335,"type":23},"2025-05-15",{"name":40,"class":41},""]